Chimeric antigen receptor T-cell therapy: unleashing the power of immunity

1. Bourbon E, Ghesquières H, Bachy E. CAR-T Cells, from Principle to Clinical Applications. Bull Cancer. 2021;108(10S):S4-S17. DOI: https://doi.org/10.1016/j.bulcan.2021.02.017

2. Park J, Geyer M, Brentjens R. CD19-Targeted CAR T-Cell Therapeutics for Hematologic Malignancies: Interpreting Clinical Outcomes to Date. Blood. 2016;127(26):3312-20. DOI: https://doi.org/10.1182/blood-2016-02-629063

3. Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B. From Bench to Bedside: the History and Progress of CAR T Cell Therapy. Front Immunol. 2023;14:1188049. DOI: https://doi.org/10.3389/fimmu.2023.1188049

4. Park J, Geyer M, Brentjens R. CD19-Targeted CAR T-Cell Therapeutics for Hematologic Malignancies: Interpreting Clinical Outcomes to Date. Blood. 2016;127(26):3312-20. DOI: https://doi.org/10.1182/blood-2016-02-629063

5. Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in Children and Young Adults with B-cell Lymphoblastic Leukemia. N Engl J Med.2018;378:439-48. DOI: https://doi.org/10.1056/NEJMoa1709866

6. Locke F, Ghobadi A, Jacobson C, Miklos D, Lekakis L, Oluwole O, et al. Long-term Safety and Activity of Axicabtagene Ciloleucel in Refractory Large B-cell Lymphoma (ZUMA-1): a Single-Arm, Multicentre, Phase 1-2 trial. Lancet Oncol. 2019;20(1):31-42. DOI: https://doi.org/10.1016/S1470-2045(18)30864-7

7. Schuster S, Tam C, Borchmann P, Worel N, McGuirk J, Holte H, et al. Long-Term Clinical Outcomes of Tisagenlecleucel in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (JULIET): A Multicentre, Open-Label, Single-Arm, Phase 2 Study. Lancet Oncol. 2021;22(10):1403-15. DOI: https://doi.org/10.1016/S1470-2045(21)00375-2

8. Abramson J, Palomba M, Gordon L, Lunning M, Wang M, Arnason J, et al. Lisocabtagene Maraleucel for Patients with Relapsed or Refractory Large B-Cell Lymphomas (TRANSCEND NHL 001): A Multicentre Seamless Design Study. Lancet. 2020;396(10254):839-52. DOI: https://doi.org/10.1016/S0140-6736(20)31366-0.)

9. Kersten M, Qiao Y, Shah R, Solem C, Snider J, To C, et al. Quality-Adjusted Time without Symptoms or Toxicity: Analysis of Axicabtagene Ciloleucel versus Standard of Care in Patients with Relapsed/Refractory Large B Cell Lymphoma. Transplant Cell Ther. 2023;29(5):335.e1-335.e8. DOI: https://doi.org/10.1016/j.jtct.2023.01.008

10. Kamdar M, Solomon S, Arnason J, Johnston P, Glass B, Bachanova V, et al. Lisocabtagene Maraleucel Versus Standard of Care with Salvage Chemotherapy Followed by Autologous Stem Cell Transplantation As Second-Line Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (TRANSFORM): Results from an Interim Analysis of an Open-Label, Randomised, Phase 3 Trial. Lancet. 2022;399(10343):2294-308. DOI: https://doi.org/10.1016/S0140-6736(22)00662-6

11. Boardman A, Salles G. CAR T-Cell Therapy in Large B Cell Lymphoma. Hematol Oncol. 2023;41 Suppl 1(Suppl 1):112-8. DOI: https://doi.org/10.1002/hon.3153

12. Munshi N, Anderson L Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021;384(8):705-16. DOI: https://doi.org/10.1056/NEJMoa2024850

13. Berdeja J, Madduri D, Usmani S, Jakubowiak A, Agha M, Cohen A, et al. Ciltacabtagene Autoleucel, A B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma (CARTITUDE-1): A Phase 1b/2 Open-Label Study. Lancet. 2021;398(10297):314-24. DOI: https://doi.org/10.1016/S0140-6736(21)00933-8

14. Manier S, Ingegnere T, Escure G, Prodhomme C, Nudel M, Mitra S, et al. Current State and Next-Generation CAR-T Cells in Multiple Myeloma. Blood Rev. 2022;54:100929. DOI: https://doi.org/10.1016/j.blre.2022.100929

15. Lin H, Cheng J, Mu W, Zhou J, Zhu L. Advances in Universal CAR-T Cell Therapy. Front Immunol. 2021;12:744823. DOI: https://doi.org/10.3389/fimmu.2021.744823

16. Mei H, Li C, Jiang H, Zhao X, Huang Z, Jin D, et al. A Bispecific CAR-T Cell Therapy Targeting BCMA and CD38 in Relapsed or Refractory Multiple Myeloma. J Hematol Oncol. 2021;14(1):161. DOI: https://doi.org/doi.org/10.1186/s13045-021-01170-7

17. Pan K, Farrukh H, Chittepu V, Xu H, Pan C, Zhu Z. CAR Race to Cancer Immunotherapy: from CAR T, CAR NK To CAR Macrophage Therapy. J Exp Clin Cancer Res. 2022;41(1):119. DOI: https://doi.org/10.1186/s13046-022-02327-z

18. Wang S, Yang Y, Ma P, Zha Y, Zhang J, Lei A, et al. CAR-Macrophage: an Extensive Immune Enhancer to Fight Cancer. EBioMedicine. 2022;76:103873. DOI: https://doi.org/10.1016/j.ebiom.2022.103873

19. Chang Y, Syahirah R, Wang X, Jin G, Torregrosa-Allen S, Elzey B, et al. Engineering Chimeric Antigen Receptor Neutrophils from Human Pluripotent Stem Cells for Targeted Cancer Immunotherapy. Cell Rep. 2022;40:111128. DOI: https://doi.org/10.1016/j.celrep.2022.111128